Molecular Residual Disease (MRD) for Pharma

MRD allows a faster time to market for pharmaceutical companies by increasing clinical trials efficiency while reducing overall cost

MRD (Molecular Residual Disease) allows a faster time to market for pharmaceutical companies by increasing clinical trials efficiency while reducing overall cost. MRD which refers to the presence of circulating tumor DNA in the blood, can be tested at multiple time points in the patient journey and might be used for several applications during the clinical trial, increasing its efficiency, reducing overall costs, and demonstrating the durability of treatment response.

 

Why conduct clinical trials with MRD monitoring?

To ensure an accurate enrolment

Guide patient selection based on biopsy mutation signature and blood-based MRD.

To evaluate treatment efficacy most quickly

Tested at multiple time-points during the course of treatment, MRD assessment is used to monitor patient response over time.

To compare two treatment approaches

Providing deep insights on treatment efficiency enables the development of an informed treatment strategy.

To adapt therapy intensity according to MRD follow-up

With the accurate tumor burden measurement as indicator, clinicians can precisely adapt the treatment intensity.

To adapt maintenance duration

Collect enough data to ensure that the trial stays on track  and that the drug or therapy is working as intended.

To introduce Early Rescue Intervention (ERI) strategy

The implementation of MRD testing supports the prevention of over and under treatment and may become a surrogate biomarker for accelerated drug development and operational cure.

Clinical utility of the MRD testing

MRD testing eliminates uncertainty throughout the treatment journey and provides a simple way of monitoring how patients are responding to their current treatment in real time.

A standardized workflow

Our standardized workflow from the test shipment to providing MRD report has been designed to ensure consistency, accuracy, and efficiency at every stage of the process.

Tests shipment

After confirmation of the order, we dispatch the test kits

All included test

After confirmation of the order, we dispatch the test kits, which include a solid biopsy block/slides holder and a barcoded blood collection tube, to the designated medical institution.

Sequencing

Filter out noise and derive patient specific cancer mutational signature

Whole genome sequencing

We identify the genetic pattern of a patient’s tumor using thousands of data points across the entire genome.

Data processing

MRD technology utilizes artificial intelligence that recognizes patient-specific cancer patterns

AI & Advanced Signal Processing

MRD technology utilizes artificial intelligence that recognizes tumor specific genomic patterns to provide unprecedented acuity in cancer detection and monitoring.

Monitoring report

Our team of oncology experts reviews each report
        

Clinical validation by scientific team

Our team of oncology experts reviews each report before making it available for the clinician

Frequently Asked Questions

C2inform is a personalized qualitative diagnostic tumor informed test for the circulating tumor DNA (ctDNA) – based Molecular Residual Disease (MRD) assessment by using whole-genome sequencing (WGS) data for patients previously diagnosed with solid cancer.

MRD test is designed to be highly sensitive and specific. It can detect extremely low levels of circulating tumor DNA (ctDNA) in a patient’s blood, allowing for the identification of residual cancer cells that might go undetected by conventional biomarker tests.

MRD test provides results in the form of a binary score (positive or negative).

Test Positive: Estimated detection score is above or equal to a pre-defined threshold value – indicates MRD detection

Test Negative: Estimated detection score is below a pre-defined threshold value – indicates MRD non-detection. A negative test result does not definitely indicate the absence of cancer. 

Data is generated from WGS analysis of the following specimen types from each patient: Tumor tissue sample (Formalin Fixed Paraffin Embedded (FFPE)), whole blood for both germline DNA from Peripheral Blood Mononuclear Cells (PBMCs), and plasma for circulating tumor DNA (ctDNA).